Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of JNJ-78278343 in advanced prostate cancer
NL-OMON53995Phase 1Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of pasritamig in prostate cancer (PCa) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Recommended Phase 2 dose determination in Part 1 and Safety at RP2D in Part 2. Started Oct 2021; status: recruiting.
02
Drugs
pasritamig
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON53995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53995.